These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 31312198)

  • 41. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
    van Beek N; Schulze FS; Zillikens D; Schmidt E
    Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lichen planus pemphigoides is a heterogeneous disease: a report of five cases studied by immunoelectron microscopy.
    Bouloc A; Vignon-Pennamen MD; Caux F; Teillac D; Wechsler J; Heller M; Lebbé C; Flageul B; Morel P; Dubertret L; Prost C
    Br J Dermatol; 1998 Jun; 138(6):972-80. PubMed ID: 9747357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida.
    Iwata H; Kitajima Y
    Exp Dermatol; 2013 Jun; 22(6):381-5. PubMed ID: 23651418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement-independent blistering mechanisms in bullous pemphigoid.
    Iwata H; Ujiie H
    Exp Dermatol; 2017 Dec; 26(12):1235-1239. PubMed ID: 28418613
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 120-kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis.
    Roh JY; Yee C; Lazarova Z; Hall RP; Yancey KB
    Br J Dermatol; 2000 Jul; 143(1):104-11. PubMed ID: 10886143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.
    Shimanovich I; Mihai S; Oostingh GJ; Ilenchuk TT; Bröcker EB; Opdenakker G; Zillikens D; Sitaru C
    J Pathol; 2004 Dec; 204(5):519-27. PubMed ID: 15538734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bullous lichen planus and lichen planus pemphigoides--clinico-pathological comparisons.
    Gawkrodger DJ; Stavropoulos PG; McLaren KM; Buxton PK
    Clin Exp Dermatol; 1989 Mar; 14(2):150-3. PubMed ID: 2598489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lichen planus pemphigoides treated with ustekinumab.
    Knisley RR; Petropolis AA; Mackey VT
    Cutis; 2017 Dec; 100(6):415-418. PubMed ID: 29360890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
    Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
    Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coexisting lichen planus and bullous pemphigoid or lichen planus pemphigoides?
    Lang PG; Maize JC
    J Am Acad Dermatol; 1983 Jul; 9(1):133-40. PubMed ID: 6350379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
    Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
    Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Rare variants of pemphigoid diseases].
    Yilmaz K; Kiehne C; Holtsche MM; Schmidt E
    Dermatologie (Heidelb); 2022 Dec; 74(12):937-947. PubMed ID: 37847383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies.
    Sitaru C; Dähnrich C; Probst C; Komorowski L; Blöcker I; Schmidt E; Schlumberger W; Rose C; Stöcker W; Zillikens D
    Exp Dermatol; 2007 Sep; 16(9):770-7. PubMed ID: 17697150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.
    Karsten CM; Beckmann T; Holtsche MM; Tillmann J; Tofern S; Schulze FS; Heppe EN; Ludwig RJ; Zillikens D; König IR; Köhl J; Schmidt E
    Front Immunol; 2018; 9():488. PubMed ID: 29599777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lichen planus pemphigoides induced by anti-PD-1 antibody: A case only involved in oral mucosa with excellent topical treatment efficiency.
    Wang S; Sun J; Deng S; Wu L; Li W; Ye T; Wu F; Wu Y; Zhou H
    J Cutan Pathol; 2024 Feb; 51(2):114-118. PubMed ID: 37846754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lichen planus pemphigoides: identification of 180 kd hemidesmosome antigen.
    Tamada Y; Yokochi K; Nitta Y; Ikeya T; Hara K; Owaribe K
    J Am Acad Dermatol; 1995 May; 32(5 Pt 2):883-7. PubMed ID: 7722050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1/2 inhibitor.
    Moussa A; Colla TG; Asfour L; Bhoyrul B; Sinclair RD
    Clin Exp Dermatol; 2022 Nov; 47(11):2040-2041. PubMed ID: 35980165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical features and practical diagnosis of bullous pemphigoid.
    Schmidt E; della Torre R; Borradori L
    Immunol Allergy Clin North Am; 2012 May; 32(2):217-32, v. PubMed ID: 22560135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade.
    Wat M; Mollanazar NK; Ellebrecht CT; Forrestel A; Elenitsas R; Chu EY
    J Cutan Pathol; 2022 Nov; 49(11):978-987. PubMed ID: 36054729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.